GRAIL, Inc.
GRAL
Positions held
Your positionsGRAL isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- GRAIL, Inc. operates in the rapidly growing diagnostics and research sector, focusing on innovative cancer detection technologies that are gaining traction in the healthcare market.
- Revenue increased by 10% compared to the prior quarter, reaching $45 million.
- The gross margin improved to -28.1%, up from -35.1% in the previous quarter.
- Despite its potential, GRAIL, Inc. has a high debt-to-equity ratio of 3.591, indicating significant leverage that could pose risks.
- The operating margin remains negative at -331.998% for the latest quarter, reflecting ongoing challenges in profitability.
- Net income for the latest quarter was -110.247 million, continuing a trend of substantial losses.
Fundamentals
| Market cap | $5.92B | Enterprise value | $5.15B | Trailing P/E | — | Forward P/E | -16.07 |
| PEG | — | Price / book | 2.33 | Beta | 2.84 | Dividend yield | 0.00% |
| Revenue growth | 25.7% | Earnings growth | — | Gross margin | 49.7% | Operating margin | -3.3% |
| Profit margin | -2.4% | ROE | -16.1% | ROA | -12.0% | Debt / equity | 0.04 |
| Current ratio | 10.95 | Free cash flow | -$103.58M | Analyst recommendation | buy | Mean target | $116.10 |
| 52w high | $166.48 | 52w low | $41.50 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $44.7M | $40.8M | $43.6M | $36.2M | $35.5M |
| Op margin | -332.0% | -332.9% | -285.4% | -346.2% | -368.1% |
| Net income | -$110M | -$93.2M | -$99.2M | -$89.0M | -$114M |
| Gross margin | -28.1% | -35.1% | -25.5% | -37.9% | -50.0% |
| Gross profit | -$12.6M | -$14.3M | -$11.1M | -$13.7M | -$17.8M |
| Operating income | -$148M | -$136M | -$124M | -$125M | -$131M |
- Revenue +10% vs prior quarter ($45M vs $41M).
- Gross margin -28.1% (was -35.1% prior quarter).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $147M | $126M | $93.1M | $55.5M |
| Op margin | -363.0% | -611.7% | -855.9% | -1336.6% |
| Net income | -$408M | -$2.0B | -$1.5B | -$5.4B |
| Gross margin | -42.5% | -62.1% | -102.7% | -209.6% |
| Gross profit | -$62.6M | -$78.0M | -$95.6M | -$116M |
| Operating income | -$534M | -$768M | -$797M | -$742M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · 2 Growth Stocks to Buy in October
2026-10-08 · Grail Insider Sold Shares Worth $1,152,528, According to a Recent SEC Filing
2026-10-08 · Grail Insider Sold Shares Worth $3,457,585, According to a Recent SEC Filing
2026-10-07 · Why CVS Is ‘Insanely Cheap,’ ON Semi a Laggard Catching Up, and Grail Too Expensive to Chase
2026-10-05 · GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026
2026-10-04 · Jim Cramer Says This Stock Could Rise Like Moderna (MRNA)
2026-10-04 · Grail Stock Has Skyrocketed 171% in 6 Months. Where Will It Be in 5 Years?
2026-10-03 · Why GRAIL (GRAL) Is Up 12.9% After Positive FDA Panel Verdict On Galleri Trial Results
2026-10-02 · UBS Adjusts GRAIL Price Target to $175 From $105, Maintains Buy Rating
2026-09-30 · 3 Reasons to Buy Grail (GRAL) Hand Over Fist in October
2026-09-30 · Grail Stock Has Soared 180% in 6 Months. Here's Why the Stock Has More Room to Run.
2026-09-30 · Why Grail Stock Skyrocketed Nearly 70% In A Week. What To Watch Next.
Price (daily)
Full chart · RSI · MACD · patterns